-
公开(公告)号：US20060105949A1
公开(公告)日：2006-05-18
申请号：US11240937
申请日：2005-09-30
摘要： The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH) In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer. The anticancer drug of the latter mixture may be one selected from the group of drugs including mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
摘要翻译： 本发明提供用于抑制前列腺腺癌，胃癌，乳腺癌，子宫内膜，卵巢癌或其他上皮分泌性癌症或良性前列腺增生症（BPH）的生长的药物组合物和方法。在一个实施方案中，药物组合物包括人rHuPSP94，其抗原部分 ，及其功能上相当的多肽。 在另一个实施方案中，药物组合物包括人rHuPSP94，其抗原部分和其功能等同多肽的混合物，以及抗癌药物，其可以以适当的剂型，剂量和剂量方案施用于患有例如 前列腺腺癌，胃癌，乳腺癌，子宫内膜癌，卵巢癌或其他上皮分泌性癌症，良性前列腺增生或（BPH）胃肠癌。 后者混合物的抗癌药可以是选自丝裂霉素，伊达比星，顺铂，5-氟尿嘧啶，甲氨蝶呤，阿霉素，道宁霉素，紫杉醇，紫杉醇衍生物及其混合物的药物组。
-
公开(公告)号：US20050026833A1
公开(公告)日：2005-02-03
申请号：US10857358
申请日：2004-06-01
IPC分类号： A61K38/17 , C07K14/47 , G01N33/574 , G01N33/84
CPC分类号： C07K14/47 , A61K38/1709 , G01N33/57434 , G01N33/84 , G01N2333/635 , G01N2500/00
摘要： The present invention discloses the use of PSP-94, PCK3145 and other derivatives and biologically active analogues for treating a patient having a condition such as metastasis, metastatic cancer, a condition associated with elevated levels of parathyroid hormone-related protein (PTHrP), PTHrP-induced osteolysis and/or hypercalcemia of malignancy. These compounds were found to be effective treatment modalities for bone metastasis caused by prostate cancer. Furthermore, decrease in cellular and plasma PTHrP levels as well as plasma calcium levels observed by treatment with such compound can serve as useful biochemical markers for monitoring the efficacy of these anti-metastatic compounds.
摘要翻译： 本发明公开了使用PSP-94，PCK3145等衍生物和生物活性类似物治疗患有转移，转移性癌症的病人，与甲状旁腺激素相关蛋白（PTHrP）水平升高相关的病症，PTHrP 诱发的骨质溶解和/或恶化的高钙血症。 发现这些化合物是由前列腺癌引起的骨转移的有效治疗方式。 此外，通过用这种化合物治疗观察到的细胞和血浆PTHrP水平以及血浆钙水平的降低可以作为监测这些抗转移化合物的功效的有用的生物化学标记物。
-
公开(公告)号：US08410300B2
公开(公告)日：2013-04-02
申请号：US12311122
申请日：2007-09-20
申请人： Brent Richard Stranix , Jean-Francois Lavallee , Nicolas LeBerre , Valerie Perron , Dominik Herbart , Guy Milot , Chandra Panchal
发明人： Brent Richard Stranix , Jean-Francois Lavallee , Nicolas LeBerre , Valerie Perron , Dominik Herbart , Guy Milot , Chandra Panchal
IPC分类号： C07C309/32
CPC分类号： C07C311/41 , C07C271/22 , C07C311/42 , C07C2601/14 , C07D213/56 , C07D213/82 , C07D265/36 , C07D307/79 , C07D317/62 , C07D319/18 , C07D405/12 , C07D413/12 , C07F9/06 , C07F9/091 , C07F9/58
摘要： The present invention provides HIV protease inhibitors of formulas I, IA, IB, Ib or II, or pharmaceutically acceptable salts thereof, wherein R2 may be, for example, 2-pyridyl-CH2—, 3 -pyridyl-CH2—, 4-pyridyl-CH2—, a sulfonyl group as described in the formulas herein including benzenesulfonyl or thiophenesulfonyl groups, R2a—CO—, R2a being selected from the group consisting of piperonyl, 2-pyrazinyl (unsubstituted or substituted with H, or an alkyl of 1 to 4 carbon atoms) or a picolylamine group as described herein, wherein R3 may be, for example, a phenyl group or diphenylmethyl group as described herein, and wherein Cx may be, for example, COOH, CONR5R6, CH2OH or CH2OR7.
摘要翻译： 本发明提供式I，IA，IB，Ib或II的HIV蛋白酶抑制剂或其药学上可接受的盐，其中R 2可以是例如2-吡啶基-CH 2 - ，3-吡啶基-CH 2 - ，4-吡啶基 -CH 2 - ，如本文所述的磺酰基，包括苯磺酰基或噻吩磺酰基，R2a-CO-，R2a选自胡椒基，2-吡嗪基（未取代或被H取代或由1至 4个碳原子）或吡啶甲基胺，其中R 3可以是例如本文所述的苯基或二苯基甲基，并且其中C x可以是例如COOH，CONR 5 R 6，CH 2 OH或CH 2 OR 7。
-
公开(公告)号：US20050148514A1
公开(公告)日：2005-07-07
申请号：US11004273
申请日：2004-12-02
申请人： Chandra Panchal , Jinzi Wu , Richard Beliveau , Marcia Ruiz , Seema Garde , Borhane Annabi , Sylvie Lamy , Mounia Bouzeghrane , Luc Daigneault , Robert Hawkins
发明人： Chandra Panchal , Jinzi Wu , Richard Beliveau , Marcia Ruiz , Seema Garde , Borhane Annabi , Sylvie Lamy , Mounia Bouzeghrane , Luc Daigneault , Robert Hawkins
CPC分类号： A61K38/10 , A61K38/1709 , C07K14/47 , C12N9/6491
摘要： Angiogenesis, the formation of new blood vessels, is an integral part of normal physiological and developmental processes as well as several pathologies, ranging from tumor growth and metastasis to inflammation and ocular disease. Methods and compositions are provided for controlling normal angiogenesis and for treating angiogenesis associated or mediated diseases.
摘要翻译： 血管生成新血管的形成是正常的生理和发育过程以及从肿瘤生长和转移到炎症和眼部疾病的几种病理学的组成部分。 提供了用于控制正常血管发生和治疗血管生成相关或介导的疾病的方法和组合物。
-
公开(公告)号：US20100184974A1
公开(公告)日：2010-07-22
申请号：US12311122
申请日：2007-09-20
申请人： Brent Richard Stranix , Jean-Francois Lavallee , Nicolas LeBerre , Valerie Perron , Dominik Herbart , Guy Milot , Chandra Panchal
发明人： Brent Richard Stranix , Jean-Francois Lavallee , Nicolas LeBerre , Valerie Perron , Dominik Herbart , Guy Milot , Chandra Panchal
IPC分类号： C07D265/36 , C07F9/09 , C07C317/36 , C07D265/30 , C07D231/18 , C07D307/64 , C07D233/84 , C07D239/557 , C07D333/34
CPC分类号： C07C311/41 , C07C271/22 , C07C311/42 , C07C2601/14 , C07D213/56 , C07D213/82 , C07D265/36 , C07D307/79 , C07D317/62 , C07D319/18 , C07D405/12 , C07D413/12 , C07F9/06 , C07F9/091 , C07F9/58
摘要： The present invention provides HIV protease inhibitors of formulas I, IA, IB, Ib or II, or pharmaceutically acceptable salts thereof, wherein R2 may be, for example, 2-pyridyl-CH2—, 3-pyridyl-CH2—, 4-pyridyl-CH2—, a sulfonyl group as described in the formulas herein including benzenesulfonyl or thiophenesulfonyl groups, R2a—CO)—, R2a being selected from the group consisting of piperonyl, 2-pyranzinyl (unsubstituted or substituted with H, or an alkyl of 1 to 4 carbon atoms) or a picolylamine group as described herein, wherein R3 may be, for example, a phenyl group or diphenylmethyl group as described herein, and wherein Cx may be, for example, COOH, CONR5R6, CH2OH or CH2OR7.
摘要翻译： 本发明提供式I，IA，IB，Ib或II的HIV蛋白酶抑制剂或其药学上可接受的盐，其中R 2可以是例如2-吡啶基-CH 2 - ，3-吡啶基-CH 2 - ，4-吡啶基 -CH 2 - ，如本文所述的磺酰基，包括苯磺酰基或噻吩磺酰基，R2a-CO） - ，R2a选自胡椒基，2-吡嗪基（未取代或被H取代或者为1的烷基） 至4个碳原子）或吡啶基胺基，其中R 3可以是例如本文所述的苯基或二苯基甲基，并且其中C x可以是例如COOH，CONR 5 R 6，CH 2 OH或CH 2 OR 7。
-
公开(公告)号：US07655631B2
公开(公告)日：2010-02-02
申请号：US11240937
申请日：2005-09-30
摘要： The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH) In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer. The anticancer drug of the latter mixture may be one selected from the group of drugs including mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
摘要翻译： 本发明提供用于抑制前列腺腺癌，胃癌，乳腺癌，子宫内膜，卵巢癌或其他上皮分泌性癌症或良性前列腺增生症（BPH）的生长的药物组合物和方法。在一个实施方案中，药物组合物包括人rHuPSP94，其抗原部分 ，及其功能上相当的多肽。 在另一个实施方案中，药物组合物包括人rHuPSP94，其抗原部分和其功能等同多肽的混合物，以及抗癌药物，其可以以适当的剂型，剂量和剂量方案施用于患有例如 前列腺腺癌，胃癌，乳腺癌，子宫内膜癌，卵巢癌或其他上皮分泌性癌症，良性前列腺增生或（BPH）胃肠癌。 后者混合物的抗癌药可以是选自丝裂霉素，伊达比星，顺铂，5-氟尿嘧啶，甲氨蝶呤，阿霉素，道宁霉素，紫杉醇，紫杉醇衍生物及其混合物的药物组。
-
公开(公告)号：US20060029984A1
公开(公告)日：2006-02-09
申请号：US11154673
申请日：2005-06-17
IPC分类号： G01N33/567 , C07K16/30
CPC分类号： G01N33/57434 , C07K14/47 , C07K16/18 , C07K16/3069 , C07K2317/32 , Y10S435/975 , Y10T436/105831
摘要： In the serum, PSP94 occurs as a free form or is associated with a carrier protein. PSP94 in its bound form has been quantified in the blood of prostate cancer patients and these measurements have shown utility as evaluation or prognosis of prostate cancer. Diagnostic assays, methods, and kits for detecting a free form of PSP94, and reagents such as antibodies able to bind to a free form of PSP94 are disclosed herein.
-
8.发明申请METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS 审中-公开提高蛋白酶抑制剂和蛋白酶抑制剂前体药物动力学的方法公开(公告)号：US20060287316A1
公开(公告)日：2006-12-21
申请号：US11380291
申请日：2006-04-26
申请人： Jinzi Wu , Brent Stranix , Michael Ge , Guy Milot , Marco Petrella , Chandra Panchal
发明人： Jinzi Wu , Brent Stranix , Michael Ge , Guy Milot , Marco Petrella , Chandra Panchal
IPC分类号： A61K31/5375 , A61K31/4965 , A61K31/498 , A61K31/551 , A61K31/445 , A61K31/44 , A61K31/522 , A61K31/47 , A61K31/18
CPC分类号： A61K31/135 , A61K31/18 , A61K31/4196 , A61K31/44 , A61K31/445 , A61K31/47 , A61K31/4965 , A61K31/498 , A61K31/513 , A61K31/522 , A61K31/5375 , A61K31/551 , A61K31/661 , A61K45/06
摘要： The present invention provides methods for improving the pharmacokinetics of protease inhibitors and protease inhibitor precursors and pharmaceutical composition comprising protease inhibitors or protease inhibitor precursors of formula I and a cytochrome P450 monooxigenase inhibitor; when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1 may be, for example, (HO)2P(O)—, (NaO)2P(O)—, alkyl-CO— or cycloalkyl-CO—, wherein X may be, for example, F, Cl, and Br, and wherein R2 and R3 are as defined herein.
摘要翻译： 本发明提供了改善蛋白酶抑制剂和蛋白酶抑制剂前体的药代动力学的方法和包含式I的蛋白酶抑制剂或蛋白酶抑制剂前体和细胞色素P450单氧原酶抑制剂的药物组合物; 当式I化合物包含氨基时，其药学上可接受的铵盐，其中R 1可以是例如（HO）2 P（O） - ， （NaO）2 P（O） - ，烷基-CO-或环烷基-CO-，其中X可以是例如F，Cl和Br，并且其中R 2， / SUB和R 3'如本文所定义。
-
公开(公告)号：US07053058B2
公开(公告)日：2006-05-30
申请号：US09977406
申请日：2001-10-15
IPC分类号： A61K38/18 , A61K38/16 , C07K14/475
摘要： The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer. The anticancer drug of the latter mixture may be one selected from the group of drugs including mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
-
公开(公告)号：US20050147601A1
公开(公告)日：2005-07-07
申请号：US11004270
申请日：2004-12-02
申请人： Chandra Panchal , Jinzi Wu , Richard Beliveau , Marcia Ruiz , Seema Garde , Borhane Annabi , Sylvie Lamy , Mounia Bouzeghrane , Luc Daigneault , Robert Hawkins
发明人： Chandra Panchal , Jinzi Wu , Richard Beliveau , Marcia Ruiz , Seema Garde , Borhane Annabi , Sylvie Lamy , Mounia Bouzeghrane , Luc Daigneault , Robert Hawkins
IPC分类号： A61K38/10 , A61K38/17 , A61K38/46 , A61K38/52 , A61K48/00 , A61P35/00 , C07H21/04 , C07K14/47 , C12N9/64 , C12Q1/68
CPC分类号： A61K38/1709 , A61K38/10 , A61K38/17 , A61K38/46 , A61K38/52 , A61K48/00 , C07H21/04 , C07K14/47 , C12N9/64 , C12N9/6491 , C12Q1/68
摘要： Matrix metalloproteinases (MMPs) play an important role in morphogenesis, angiogenesis, wound healing, and in certain disorders such as rheumatoid arthritis, tumor invasion and metastasis. MMPs are thought to be regulated by a variety of cytokines, growth factors, hormones and phorbol esters. This regulation occurs on three levels; alteration of gene expression, activation of the latent zymogen and inhibition by the tissue inhibitors of metalloproteinases (TIMP). We report here a new agent that regulates the level of MMPs.
摘要翻译： 基质金属蛋白酶（MMP）在形态发生，血管生成，伤口愈合以及某些疾病如类风湿性关节炎，肿瘤浸润和转移中起重要作用。 认为MMP被多种细胞因子，生长因子，激素和佛波酯所调节。 这种规定发生在三个层次上 基因表达的改变，潜在酶原的活化和金属蛋白酶（TIMP）的组织抑制剂的抑制。 我们在这里报告一种调节MMPs水平的新药物。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.023 秒)
